Clinical Trials
30 trialsSintilimab Combined With Anlotinib and Taxane-Based Chemotherap for Recurrent/Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
A Prospective, Single-arm Clinical Study of Liposomal Mitoxantrone Combination Regimen in the Treatment of Relapsed and Refractory Solid Tumors in Children, Adolescents and Young Adults
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
MBC-EA
Sun Yat-sen University
A Study of Bemosubaiabimab Combined With Anlotinib and Radiotherapy and Chemotherapy for the Treatment of Oligometastatic Esophageal Cancer
The First Affiliated Hospital with Nanjing Medical University
Study on the Treatment of HER2-negative Breast Cancer Brain Metastases With Radiotherapy Combined With Anlotinib
The First Affiliated Hospital with Nanjing Medical University
Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal Cancer
Shanghai Changzheng Hospital
Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small MoleculeĀ±SBRT as Second-line Therapy in Metastatic Pancreatic Cancer Patients
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
MAGNATE-S
Shanghai 6th People's Hospital
A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy
Zhejiang Cancer Hospital
To Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Capsule in Postoperative Non-pCR Patients With Non-small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
FASCINATE-N
Fudan University
Neoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03)
First Affiliated Hospital of Zhejiang University
PCA
Fudan University
Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC
Zhejiang Cancer Hospital
Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
SAIB
First Affiliated Hospital of Zhejiang University
Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.
Sun Yat-sen University
Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion
Tianjin Medical University Second Hospital
Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer
West China Hospital
WUKONG-32-RW
Hunan Province Tumor Hospital
WUKONG-32
Hunan Province Tumor Hospital
Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric Cancer With ECOG 2 (APICAL-GC)
Shanghai Changzheng Hospital
Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC
Fudan University
Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer
Zhongnan Hospital
Clinical Application of Near-infrared Whole Body Heat Shock Multimodal Technique in Treatment of Castration-resistant Prostate Cancer
Zhejiang Hospital
Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma
Fudan University
RCT-PAAG
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer
Zhejiang Cancer Hospital